Xencor, Inc Gain (Loss) Related to Litigation Settlement
Xencor, Inc (XNCR) reported Gain (Loss) Related to Litigation Settlement of $187.50 thousand for the 12-month period ending 2015-12-31, per its 10-Q filed 2017-11-08.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2017-11-08
| Period end | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|
| 2015-12-31 | $187.50K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |